嵌合抗原受体T细胞免疫疗法治疗B细胞淋巴瘤的研究进展

Progress on chimeric antigen receptor T lymphocytes in treating B-cell lymphoma

B细胞淋巴瘤(B cell lymphoma)因其异质性,患者极易复发,因此成为肿瘤治疗的难题之一。嵌合抗原受体T细胞(chimeric antigen receptor T-cell, CAR-T)免疫疗法有良好的治疗效果且具精准、快速和高效的特点,成为最具前景的治疗癌症的方法之一。目前,CAR-T免疫疗法在治疗B细胞淋巴瘤上得以成功的应用,同时,FDA已批准相关产品应用于治疗B细胞淋巴瘤,一定程度上弥补了常规治疗B细胞淋巴瘤的方法。现就CAR-T免疫疗法的发展历程、主要靶点及其策略研究作一概述,为治疗B细胞淋巴瘤提供可参考的思路。

In treatment of B-cell lymphoma is one of the difficult problems in tumor because of its heterogeneity and high recurrence. At present,chimeric antigen receptor T cell(CAR-T) immunotherapy has become one of the most promising methods in treatment of cancer due to its good therapeutic efficacy and accuracy. At the moment, the FDA has approved the product of CAR-T for the treatment of B-cell lymphoma, and CAR-T has been successfully applied for treating B-cell lymphoma, which overcomes the conventional treatment of B-cell lymphoma to some extent. In providing a reference in this area, we will review the research progress on the development of CAR-T, the types of CAR-T, in relation to the challenges and strategies in the treatment of B-cell lymphoma.